IVD CDMO Tech Transfer Readiness Package: Complete Guide for Diagnostic Manufacturers
How to prepare an IVD CDMO technology transfer readiness package — documentation requirements, process validation ownership, quality agreement structure, analytical method transfer, regulatory filing strategy, and risk mitigation under FDA 21 CFR 820/QMSR, ISO 13485, and EU IVDR.
Why the Readiness Package Determines Whether Your Tech Transfer Succeeds
Transferring an in vitro diagnostic product to a contract development and manufacturing organization is not a logistics exercise. It is a knowledge transfer problem with regulatory teeth. The CDMO must reproduce your product -- its reagent formulations, its conjugate preparations, its membrane striping, its fill-finish, its lyophilization cycle, its kit assembly sequence, its release testing -- with enough fidelity that every manufactured lot is equivalent to what your own facility produced. If any piece of that knowledge is missing, ambiguous, or locked inside the experience of a senior technician who never wrote it down, the transfer will generate out-of-specification results, failed validations, and regulatory delays that compound for months.
The document that prevents this is the technology transfer readiness package. It is the complete, structured compilation of everything the CDMO needs to reproduce your manufacturing process at commercial scale. Not a summary. Not a slide deck. The full set of manufacturing specifications, raw material definitions, process parameters, analytical methods, stability data, and quality records that together constitute the manufacturing identity of the product.
This guide covers what belongs in that package, how to organize it, how to identify and close gaps before the CDMO sees it, and how the regulatory frameworks -- FDA QMSR, ISO 13485, EU IVDR -- shape what you must document and what you must prove.
What a Tech Transfer Readiness Package Actually Contains for IVD Products
Technology transfer in the IVD context is focused on manufacturing process transfer, not product development. The product design is locked. The assay principle, the clinical intended use, the analytical performance characteristics -- those are already established in the design history file. What transfers is the operational knowledge of how to make the product consistently: the recipes, the equipment settings, the environmental controls, the in-process checks, the acceptance criteria, and the accumulated wisdom from every deviation, CAPA, and non-conformance that shaped the process into its current state.
For an IVD product, the readiness package has a documentation hierarchy that reflects the flow from product definition to manufacturing execution to quality verification.
Product Master Record (PMR) / Medical Device File: This is the top-level specification document that defines what the product is. It contains the finished product specification (description, composition, performance requirements, shelf life, storage conditions), the bill of materials with every component and raw material, the approved supplier list for each material, and references to all manufacturing procedures, test methods, labeling, and packaging specifications. Under ISO 13485 Clause 4.2.3, the medical device file is required for each device type or device family. Under the legacy FDA framework, this was the Device Master Record (DMR).
Batch Manufacturing Record (BMR): The step-by-step production instructions that an operator follows to manufacture a single batch. Every step, every in-process check, every hold point, every material addition with quantity and reference, every sign-off. The BMR is derived from the PMR but adds the operational sequence and recording fields. For an IVD reagent, a single BMR might cover buffer preparation, conjugate preparation, membrane striping, conjugate pad treatment, cutting, assembly, fill-finish, packaging, and quarantine -- or each of those might be a separate batch record depending on how the process is segmented.
Raw Material Specifications: For every input material, the package must include the specification (identity, purity, potency, physical parameters, acceptance criteria), the approved supplier or suppliers, any special handling or storage requirements, and the incoming quality control test plan. IVD raw materials are often the most critical and least documented element. The difference between a gold nanoparticle conjugate from Supplier A and Supplier B may not be visible on a CoA but can dramatically affect assay sensitivity. The readiness package must capture not just what the material specification says but what the process actually requires.
Analytical Methods and QC Release Specifications: Every test method used to release the product or intermediate must be documented in sufficient detail that the receiving site can reproduce it. This includes the method procedure, reference standards and controls, equipment requirements, calibration status, and acceptance criteria. For IVD products, release testing often includes functional performance testing (sensitivity, specificity, precision, linearity) in addition to physical and chemical testing.
Stability Data: The stability protocol, current stability data, shelf life assignment, and any ongoing stability commitments. The CDMO needs to understand the stability profile to manage storage, shipping, and any post-transfer comparability studies.
Process Validation Reports: If the process has already been validated at the originating site, the validation reports provide the documented evidence that the process works within defined parameters. These reports are the starting point for the CDMO's own validation activities.
IVD-Specific Process Documentation
The reason IVD tech transfer is distinct from general medical device or pharmaceutical tech transfer is the nature of the manufacturing processes. IVD manufacturing involves reagent chemistry, immunochemistry, molecular biology, membrane-based assembly, and precision dispensing -- processes that are sensitive to raw material lot variation, environmental conditions, and operator technique in ways that are often difficult to fully quantify.
Reagent Formulation Records
Every buffer, conjugate solution, master stock, and working solution must be documented with its complete formulation (reagent-grade water, salts, buffers, preservatives, proteins, detergents -- each with catalog numbers, concentrations, and preparation instructions), the preparation procedure (order of addition, mixing method, pH adjustment, filtration, degassing), the in-process controls (pH, conductivity, osmolality, visual appearance, bioburden), and the storage conditions and shelf life. For a lateral flow assay transfer, this might include the running buffer, the sample pad pretreatment solution, the conjugate reconstitution buffer, and the block buffer -- each a separate formulation with its own record.
Nitrocellulose Membrane Striping Parameters
Membrane striping is one of the most transfer-sensitive processes in lateral flow manufacturing. The readiness package must specify the membrane type and grade (manufacturer, catalog number, capillary flow rate, backing material), the capture reagent solutions (concentration, buffer composition, dispense rate, line position and spacing, test line and control line placement), the dispensing equipment and settings (dispense volume per drop, drop frequency, line speed, nozzle-to-membrane distance), the drying conditions (temperature, humidity, duration, airflow), and the in-process inspection criteria (line width, line intensity, line position, visual defects). Small differences in striping parameters between the originating site and the CDMO can shift assay sensitivity or generate lot-to-lot variability that triggers non-conformances.
Conjugate Pad Treatment and Drying Protocols
The conjugate pad carries the detector reagent -- typically gold nanoparticles, latex beads, or fluorescent microspheres conjugated to an antibody or antigen. The pad treatment protocol defines how the conjugate is applied (immersion, spraying, dispensing), the conjugate concentration, the pad drying conditions (temperature, humidity, duration, whether under vacuum or controlled atmosphere), and the storage conditions for dried conjugate pads. This is a process where tacit knowledge is especially important: experienced operators may adjust drying time based on ambient humidity, or recognize when a conjugate preparation looks "off" before it is measurable by any instrument parameter. Capturing this knowledge in the readiness package is essential.
Lyophilization Cycle Parameters
For IVD products that contain lyophilized reagents -- molecular diagnostic master mixes, calibrators, controls, or reagent beads -- the lyophilization cycle is a critical process that must be precisely documented. The readiness package must include the complete cycle recipe: shelf temperature ramp rates, freezing temperature and hold time, primary drying temperature and chamber pressure, secondary drying temperature and duration, and the product temperature profile that defines cycle completion. It must also specify the container closure system, the fill volume and headspace, the excipient formulation (cryoprotectants, lyoprotectants, bulking agents), and the residual moisture acceptance criteria. Lyophilization is a process where equipment differences between sites -- different shelf temperature uniformity, different condenser capacity, different pressure control precision -- can require cycle adaptation. The readiness package should document the critical process parameters and the acceptable ranges, not just the nominal set points.
Fill-Finish Specifications
Fill-finish for IVD products covers liquid reagent dispensing (bottles, vials, dropper bottles), conjugate pad impregnation, membrane lamination, and kit component assembly. The readiness package must specify fill volumes and tolerances, container closure specifications, fill accuracy verification methods, visual inspection criteria, and any special handling (cold chain, light protection, inert atmosphere). For automated filling lines, the package should document the equipment parameters that control fill accuracy and any line-specific adjustments that were developed over time.
Kit Assembly Bill of Materials and Work Instructions
A finished IVD kit is a manufactured assembly of multiple components: reagent bottles, calibrators, controls, disposable cassettes or test strips, pipettes, instruction for use, packaging inserts, and cartons. The readiness package must include the complete bill of materials for each kit configuration, the work instructions for each assembly step, the in-process quality checks, the finished product release criteria, and the packaging and labeling specifications. Kit assembly is often the simplest process technically but the most complex logistically, because it involves coordinating the availability of all components from multiple suppliers.
QC Release Testing Methods and Acceptance Criteria
Every analytical method used to release finished product or critical intermediates must be documented in sufficient detail for the CDMO to reproduce it independently. This means full method procedures, not just references to pharmacopeial chapters or internal method codes. For IVD products, release testing typically includes physical and chemical testing (appearance, pH, volume, concentration) plus functional performance testing using reference panels or characterized clinical specimens. The readiness package must define the reference materials, the test procedure, the data analysis method, and the acceptance criteria for each test.
Knowledge Transfer Beyond Documentation
The readiness package captures explicit knowledge -- what is written down, what is in the quality system documents, what the SOPs say. But manufacturing processes also rely on tacit knowledge: the things experienced operators and scientists know that never made it into a procedure. Tacit knowledge is not a failure of documentation. It is an inherent feature of complex manufacturing, and the readiness package process must explicitly address it.
Tacit Knowledge Capture
Before the readiness package is assembled, the transfer team should conduct structured interviews with the operators, technicians, and scientists who actually run the process. These interviews should cover what they do differently from the written procedure, what adjustments they make based on ambient conditions or material lots, what problems they have encountered and how they resolved them, and what they watch for that is not captured in any in-process check. For example, a conjugate preparation SOP might specify mixing for 30 minutes at room temperature. An experienced technician might know that on high-humidity days, the conjugate should be allowed to equilibrate for an additional 15 minutes before use, because the ambient moisture affects the protein conformation and therefore the conjugation efficiency. That knowledge, if not captured, will be lost when the process moves to the CDMO.
Non-Conformance History and CAPA Trends
The readiness package should include a summary of the non-conformance history for the product, organized by type and frequency. This is not just a regulatory record -- it is a practical guide for the CDMO on where the process is most vulnerable. If 60% of non-conformances over the past three years were related to membrane striping variability, the CDMO needs to know that striping is the high-risk step and should receive extra attention during process qualification. Similarly, the CAPA history reveals systemic issues that have been addressed but may recur if the corrective actions were process-specific and the CDMO's process is different.
Out-of-Specification Investigation Patterns
OOS investigations contain some of the most valuable transfer knowledge, because they document what went wrong, why, and how it was fixed. A pattern of OOS results traced to a specific raw material supplier, a specific piece of equipment, or a specific environmental condition is information the CDMO needs proactively. The readiness package should include a summary of OOS investigation conclusions and root causes, with particular attention to causes that may be site-specific.
Gap Analysis: Comparing Your Documentation Against What the CDMO Actually Needs
A gap analysis is the structured comparison between the current state of documentation and the requirements for successful transfer. It should be performed before the readiness package is shared with the CDMO, because submitting an incomplete package erodes credibility and forces the CDMO to spend discovery time identifying gaps that the sponsor should have already identified.
How to Conduct the Gap Analysis
Start with the CDMO's requirements. Most experienced IVD CDMOs have a standard technology transfer checklist or intake form that defines what they need. Request this checklist early and map your existing documentation against it. Identify three categories: documents that exist and are current, documents that exist but need updating or supplementing, and documents that do not exist and must be created.
Common gaps in IVD tech transfer packages include: raw material specifications that list acceptance criteria but not the functional rationale for those criteria, process parameters that specify nominal values but not proven acceptable ranges, analytical methods that are written for the originating site's specific equipment and require adaptation, stability data that was generated on early-process lots and may not represent current process capability, and validation reports that were completed years ago and do not reflect subsequent process changes.
Equipment and Facility Differences
One of the most consequential gaps is the difference between the originating site's equipment and the CDMO's equipment. The readiness package must identify every piece of equipment that is critical to the process and specify whether the process is equipment-agnostic (can be run on equivalent equipment with the same parameters) or equipment-specific (requires the same make and model or significant revalidation). For example, a membrane striping process developed on a specific BioDot dispenser may produce different line quality on a different dispenser model, even with identical dispense parameters. This must be identified as a gap and addressed through development studies at the CDMO before formal validation.
Regulatory Context: What the Frameworks Require
FDA QMSR and ISO 13485 Clause 7.3.8 (Design Transfer)
The FDA Quality Management System Regulation, effective February 2, 2026, incorporates ISO 13485:2016 by reference. Under this framework, design transfer is governed by ISO 13485 Clause 7.3.8, which requires documented procedures for transferring design and development outputs to manufacturing. The procedures must ensure that design outputs are verified as suitable for manufacturing before becoming final production specifications, and that production capability can meet product requirements. Results and conclusions of the transfer must be recorded.
For an IVD tech transfer to a CDMO, this means the sponsor must have documented evidence that the manufacturing specifications being transferred are complete and suitable for production at the receiving site. The readiness package is the primary evidence of that completeness. The CDMO's process qualification -- the IQ, OQ, and PQ activities -- provides the evidence of production capability.
ISO 13485 Clause 7.3.7 (Design and Development Outputs)
Clause 7.3.7 requires that design and development outputs meet the input requirements for design and development, provide appropriate information for purchasing, production, and for service provision, contain or reference product acceptance criteria, and specify the characteristics of the product that are essential for its safe and proper use. These outputs form the basis of the readiness package. If the design outputs are incomplete or ambiguous, the transfer will fail regardless of how well-structured the readiness package is.
21 CFR 820 Process Validation at the CDMO Site
Under QMSR, process validation requirements are embodied in ISO 13485 Clause 7.5.6, which requires validation of processes for production and service provision where the resulting output cannot be verified by subsequent monitoring or measurement. For IVD manufacturing, this typically applies to reagent formulation, conjugate preparation, membrane striping, lyophilization, and fill-finish -- processes where the output quality is not fully verifiable by testing the final product.
The process validation must be performed at the CDMO site, using the CDMO's equipment, personnel, and environment. The sponsor retains responsibility for ensuring that validation is adequate, even though the physical work is performed by the CDMO. The quality agreement must clearly assign validation responsibilities: who writes the validation protocol, who executes it, who reviews and approves the results, and who holds the final approval authority.
EU IVDR Implications
Under the In Vitro Diagnostic Regulation (EU 2017/746), the manufacturer must demonstrate that the manufacturing process produces devices that conform to the technical documentation and the general safety and performance requirements. Article 10(8) requires the manufacturer to ensure that devices are manufactured in accordance with the QMS and the information and instructions supplied by the manufacturer. Annex II (Technical Documentation) requires that manufacturing process data, including validation data, be available for Notified Body review.
When manufacturing is transferred to a CDMO, the Notified Body will expect to see evidence that the transfer was controlled, that the CDMO's processes were validated, and that product manufactured at the new site is equivalent to product manufactured at the original site. This comparability evidence is a regulatory requirement, not a nice-to-have.
Analytical Method Transfer
Analytical method transfer is one of the most technically demanding elements of an IVD tech transfer, because IVD release methods are often functional assays that are sensitive to reagent lots, operator technique, and environmental conditions.
Method Qualification at the Receiving Site
Each analytical method must be qualified at the CDMO to demonstrate that it performs equivalently to the originating site. This is not a full revalidation -- it is a demonstration that the method, when executed at the CDMO using the CDMO's equipment and personnel, produces results that meet the established acceptance criteria.
The method transfer protocol should specify: the methods to be transferred, the reference materials and controls to be used, the number of replicates and runs, the acceptance criteria for method performance (precision, accuracy, sensitivity, specificity as applicable), and the data analysis approach. The acceptance criteria are typically derived from the method validation data at the originating site, with allowance for normal inter-site variability.
Method Comparison Protocols
For complex functional methods -- for example, a lateral flow assay read on a reader platform, or a molecular assay run on a real-time PCR instrument -- a method comparison study may be required. This involves testing the same set of samples at both sites and comparing the results using predefined statistical criteria (correlation coefficient, bias, agreement at clinical decision points). The method comparison protocol should define the sample panel, the testing plan, the acceptance criteria, and the resolution process for discordant results.
When Methods Cannot Be Directly Transferred
Sometimes an analytical method developed at the originating site cannot be directly transferred because the CDMO uses different equipment. For example, the originating site may use a UV-Vis spectrophotometer from one manufacturer, and the CDMO may use a different model. In these cases, the method must be adapted and the adapted method must be qualified. This adds time and cost to the transfer, and it should be identified during the gap analysis so that it can be planned into the transfer timeline.
Quality Agreement Provisions for IVD Tech Transfer
The quality agreement between the sponsor and the CDMO must address the specific requirements of technology transfer, not just ongoing commercial manufacturing. The transfer phase has distinct responsibilities, timelines, and decision points that the quality agreement must capture.
Roles and Responsibilities (RACI)
During transfer, the RACI matrix must clearly define who is responsible, accountable, consulted, and informed for each activity. Critical decisions include: who approves the readiness package, who writes and approves the validation protocols, who executes the validation runs, who reviews and approves the validation reports, who makes the formal decision that the transfer is complete and the CDMO is approved for commercial production, and who has the authority to stop the transfer if non-conformances occur.
The sponsor should retain final approval authority for all validation protocols and reports, all changes to manufacturing specifications during the transfer, and the formal release of the first commercial batches. The CDMO should be responsible for executing validation activities at their site, reporting results promptly and completely, and identifying any site-specific constraints that affect the transfer.
Change Control During Transfer
Change control during the transfer period is a common source of conflict. The transfer team will inevitably discover that some process parameters need adjustment for the CDMO's equipment or environment. These adjustments must be managed through a formal change control process that both parties have agreed to in the quality agreement. The agreement should specify: the change classification system (minor, moderate, major), the approval requirements for each classification, the documentation requirements, and the process for handling emergency changes.
A practical approach is to establish a joint change control board during the transfer period, with representatives from both organizations, that meets regularly to review and approve transfer-related changes. This prevents the sponsor from being a bottleneck while maintaining control over the product's manufacturing specifications.
Raw Material Supplier Qualification
The quality agreement must address how raw material suppliers will be managed during and after the transfer. Key questions include: will the CDMO use the same suppliers specified in the readiness package, or will the CDMO propose alternate suppliers? What is the qualification process for alternate suppliers? Who approves the use of an alternate supplier? What testing is required to demonstrate that material from an alternate supplier produces equivalent product?
For IVD products, raw material changes are high-risk. A different lot of nitrocellulose membrane, a different preparation of gold nanoparticles, or a different source of monoclonal antibody can shift assay performance in ways that are not caught by standard incoming QC testing. The quality agreement should require that any raw material supplier change during and after transfer be treated as a significant change requiring sponsor approval and, where appropriate, comparability testing.
Sub-Tier Supplier Oversight
IVD supply chains often have multiple tiers. The antibody supplier may source their raw materials from sub-tier suppliers whose identity and control are not visible to the sponsor or the CDMO. The quality agreement should require that the CDMO's supplier management system extends oversight to sub-tier suppliers of critical materials, including notification requirements for sub-tier changes and the right for the sponsor to audit sub-tier suppliers upon justified request.
Risk Management During Transfer
Parallel Supply Strategy
The safest transfer strategy is to maintain production at the originating site while the CDMO ramps up, creating a parallel supply that can be drawn upon if the CDMO encounters problems. This means running down existing inventory less aggressively, planning for overlap in manufacturing capability, and accepting higher short-term costs in exchange for lower supply risk. For products with high commercial value or regulatory sensitivity, parallel supply should be maintained until the CDMO has produced at least three consecutive conforming commercial batches.
Process Validation Approach at the CDMO (IQ/OQ/PQ)
Process validation at the CDMO follows the standard IQ/OQ/PQ methodology, but with some transfer-specific considerations.
Installation Qualification verifies that the CDMO's equipment is installed correctly and meets the requirements specified in the readiness package. For IVD manufacturing equipment -- dispensers, laminators, cutters, lyophilizers, filling lines -- IQ should confirm that the equipment specifications match the process requirements and that any differences have been identified and assessed.
Operational Qualification demonstrates that the equipment operates within the specified parameter ranges using the CDMO's standard operating procedures. For IVD processes, OQ should challenge the edges of the proven acceptable ranges identified in the readiness package, not just the nominal set points. This is where the documentation quality matters most: if the readiness package only provides nominal parameters without ranges, the OQ must establish those ranges, which extends the timeline.
Performance Qualification demonstrates that the complete process, operated by trained CDMO personnel using qualified equipment and materials from approved suppliers, consistently produces product meeting all release specifications. PQ typically requires a minimum of three consecutive conforming batches, although some IVD products with high lot-to-lot variability may require more batches to demonstrate consistency.
Comparability Studies
Comparability is the demonstration that product manufactured at the CDMO is equivalent to product manufactured at the originating site. For IVD products, comparability testing should include full analytical performance (sensitivity, specificity, precision, linearity, interference), side-by-side testing of samples spanning the assay's measuring range, and assessment of any product attributes that are known to be sensitive to process variation. The comparability protocol should be written before the first PQ batch, reviewed and approved by both parties, and the results should be documented in a comparability report that becomes part of the transfer record.
Timeline Management
The initial tech transfer and kick-off to the first at-scale batch usually takes six months or more for a moderately complex IVD product. More complex products -- molecular diagnostic assays with lyophilized components, multi-analyte panels, or automated platform-specific reagents -- can take twelve to eighteen months. The timeline should be planned with explicit milestones: readiness package delivery and review, gap analysis completion, equipment qualification, method transfer, protocol approval, PQ batch execution, comparability study completion, and commercial release approval.
Common Failure Modes
Incomplete Documentation
This is the most common and most preventable failure mode. Documentation gaps are one of the main causes of delays, failed validations, and regulatory issues in technology transfer. The gaps are often in the details: process parameters specified as target values without tolerance ranges, raw material specifications that describe what the material is but not what functional properties it must have for the process, analytical methods that assume specific equipment or reagents without stating those dependencies, and work instructions that describe what to do but not what to watch for.
The solution is the gap analysis described above, performed rigorously and honestly, with input from the people who actually run the process. If a process step is not fully documented, say so. It is better to identify the gap upfront and plan to address it than to submit an incomplete package and discover the gap during a failed validation run.
Untransferable Tacit Knowledge
Some processes depend heavily on operator judgment that is difficult to codify in a written procedure. Conjugate preparation, in particular, is notorious for this -- the point at which a conjugate preparation is "done" may be determined by visual inspection by an experienced operator, not by an instrument reading. When that process transfers to a CDMO whose operators lack the same experience, the judgment element is lost.
The solution is to convert tacit knowledge into explicit knowledge before the transfer. This means developing objective in-process criteria to replace subjective judgment, training CDMO operators at the originating site before the transfer, and planning for additional development runs at the CDMO to build the operators' experience base before formal validation begins.
Analytical Method Mismatches
When the CDMO does not have the same analytical equipment as the originating site, method transfer becomes method development. This extends the timeline, increases costs, and introduces the risk that the adapted method may not perform identically to the original. The readiness package should identify every method that requires equipment-specific adaptation so that method transfer studies can begin early in the transfer timeline, parallel to equipment qualification.
Raw Material Supplier Changes
If the CDMO cannot or will not use the same raw material suppliers specified in the readiness package -- because of existing supplier relationships, geographic logistics, or volume requirements -- the qualification of alternate suppliers becomes a critical path activity. For IVD products, this is not a paperwork exercise. It requires functional testing of product manufactured with the alternate material, comparison against product manufactured with the original material, and sometimes stability studies to confirm that the alternate material does not affect shelf life. Plan for this early and budget for it explicitly.
Equipment Capability Differences
Even when the CDMO has the same type of equipment, subtle differences in capability can affect process performance. A lyophilizer with different shelf temperature uniformity may produce product with different residual moisture distribution. A dispenser with different drop volume precision may produce membrane lines with different morphology. The readiness package should document the critical-to-quality equipment capabilities, not just the equipment make and model, so that the CDMO can assess capability gaps before the transfer begins.
Building the Package: A Practical Approach
The best readiness packages are built iteratively, not assembled at the last minute. Start the package six months before the planned transfer kick-off. Begin with the documentation hierarchy -- the PMR, the BMRs, the raw material specifications, the analytical methods, the stability data, and the validation reports. Review each document for currency and completeness. Then conduct the tacit knowledge capture through operator interviews. Then perform the gap analysis against the CDMO's requirements. Then close the gaps.
CDMOs are increasingly investing in digitalized workflows, automated GMP documentation, and standardized templates that streamline the transfer process. Ask your CDMO what their standard intake format is and whether they have templates for the most common transfer documents. Aligning your package with their intake format reduces the translation effort on both sides.
The readiness package is not a deliverable that is thrown over the wall. It is the foundation of a collaborative process that requires ongoing communication, joint problem-solving, and shared commitment to getting the product right. Invest in the package, and the transfer has a strong chance of succeeding on schedule. Shortchange it, and the transfer will teach you -- expensively -- what you should have documented.
Final Considerations
CDMOs now manufacture nearly half of global biologics output, and that share is expected to reach 56% by 2029, according to industry analyst estimates. The same outsourcing trend is accelerating in IVD. As the IVD CDMO market matures, the ability to execute a clean, well-documented technology transfer is becoming a competitive differentiator -- both for sponsors who can move faster because their processes are transfer-ready, and for CDMOs who can onboard new products efficiently because they receive complete, well-organized readiness packages.
The regulatory environment reinforces this. Under QMSR, the FDA's alignment with ISO 13485 means that design transfer, process validation, and supplier management expectations are more explicit and more enforceable than ever. Under EU IVDR, Notified Bodies are scrutinizing manufacturing transfers as part of conformity assessment, particularly for Class C and Class D devices where the clinical risk is highest. A well-prepared readiness package is not just a practical tool -- it is evidence of quality system maturity that regulators expect to see.